NYSEMKT: VTAKCatheter Precision Inc Stock
$0.32-0.02 (-5.88%)
Updated Apr 17, 2025
VTAK Price
$0.32
Fair Value Price
N/A
Market Cap
$2.97M
52 Week Low
$0.24
52 Week High
$8.40
P/E
-0.05x
P/B
0.25x
P/S
3.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$420.00k
Earnings
-$16.64M
Gross Margin
90%
Operating Margin
-3,193.1%
Profit Margin
-5,190.7%
Debt to Equity
1.36
Operating Cash Flow
-$9M
Beta
1.13
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
VTAK Overview
Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. The company offers DABRA (destruction of arteriosclerotic blockages by laser radiation ablation), a minimally-invasive excimer laser and disposable catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. It also provides Pharos, an excimer laser device that emits highly concentrated ultraviolet light used in the treatment of dermatological skin disorders. The company sells its products primarily through its direct sales force in the United States. Ra Medical Systems, Inc. was founded in 2002 and is headquartered in Carlsbad, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VTAK's potential to beat the market
- VTAK doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
VTAK
RankedUnranked of 102
RankedUnranked of 102
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.82 | A | |
| $22.79 | A | |
| $13.33 | A |
Be the first to know about important VTAK news, forecast changes, insider trades & much more!
VTAK News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VTAK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VTAK is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VTAK is good value based on its book value relative to its share price (0.25x), compared to the US Medical Devices industry average (3.8x)
P/B vs Industry Valuation
VTAK is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VTAK due diligence checks available for Premium users.
Valuation
VTAK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.05x
Industry
41.14x
Market
27.98x
VTAK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.25x
Industry
3.8x
VTAK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VTAK's financial health
Profit margin
Revenue
$149.0k
Net Income
-$5.6M
Profit Margin
-7,238.9%
VTAK's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VTAK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$27.8M
Liabilities
$16.0M
Debt to equity
1.36
VTAK's short-term assets ($3.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VTAK's long-term liabilities ($13.93M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VTAK's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VTAK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.9M
Investing
$0.0
Financing
$4.5M
VTAK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VTAK vs Medical Device Stocks
Catheter Precision Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.